Clinical Trial Update: A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy [Phase 3]

View source ↗

Summary

Phase 3 trial assessing VRd followed by cilta-cel CAR-T versus Rd therapy in newly diagnosed multiple myeloma patients not planned for autologous transplant.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Rd (lenalidomide and dexamethasone) (lenalidomide+dexamethasone)
• VRd (bortezomib, lenalidomide, dexamethasone)
• ciltacabtagene autoleucel (cilta-cel) (cilta-cel)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Multiple Myeloma | Phase 3 | Status: ACTIVE_NOT_RECRUITING